A real-world data and sample compendium of frail and/or multiply treated large B-cell lymphoma (ALMANAC)

Research summary

(Diffuse) large B-cell lymphoma (D)LBCL is a cancer of the lymphatic system. Approximately 5,500 people are diagnosed with LBCL per year in the United Kingdom (UK), representing approximately 30-40% of people diagnosed with non-Hodgkin lymphoma (NHL). The usual treatment for patients newly diagnosed with LBCL is a combination of anti-cancer drugs called R-CHOP which are given for approximately 6 months. In practice, around half the patients diagnosed with LBCL are unsuitable for ‘full-dose’ and standard of care R-CHOP or Pola-R-CHP due to age-restrictions or other health conditions that increase the risk of side effects. Often, the dose has to be reduced or delayed and this is likely to reduce their effectiveness in treating the LBCL. A significant proportion (10-15%) of patients do not respond, or relapse shortly after their treatment. A further 20-25% relapse following an initial response to therapy. These patients have a poor prognosis and represent an area of unmet clinical need. Although primary and secondary care data registries collect data on treatment and management of DLBCL, the quality and completeness is varied. A better understanding of patients who are A) ineligible for first-line treatment with full dose R-CHOP and B) patients with relapsed/refractory DLBCL is desirable. This study will survey patients’ demographic and clinical characteristics, treatment pathways, and clinical outcomes in order to better characterise DLBCL and develop future studies. In addition, collection of and biobanking of relevant blood and biopsy samples linked to the data collection is designed to promote future research. Eligible patients will be enrolled by NHS sites across the UK and will be followed for a maximum of 12 months post-treatment.

Principal Investigator

Dr Danmei Xu

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

337564